L3VLUP
ProSign in

MEDP · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

MEDPLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • MEDP
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterMEDPLLY
Q3 202012 holders, $218m33 holders, $14.1bn
Q4 20208 holders, $187m29 holders, $17.3bn
Q1 20219 holders, $153m24 holders, $23.0bn
Q2 20218 holders, $156m24 holders, $27.8bn
Q3 202111 holders, $413m31 holders, $29.9bn
Q4 202112 holders, $668m31 holders, $34.7bn
Q1 20226 holders, $107m24 holders, $35.3bn
Q2 20225 holders, $97m33 holders, $42.7bn
Q3 20223 holders, $59m31 holders, $43.4bn
Q4 202210 holders, $269m31 holders, $46.6bn
Q1 202314 holders, $275m33 holders, $44.3bn
Q2 202317 holders, $468m37 holders, $59.6bn
Q3 202315 holders, $378m44 holders, $67.6bn
Q4 202314 holders, $501m45 holders, $73.6bn
Q1 202417 holders, $1.2bn41 holders, $95.3bn
Q2 202418 holders, $1.3bn43 holders, $110bn
Q3 202415 holders, $918m45 holders, $107bn
Q4 202415 holders, $1.2bn46 holders, $93.9bn
Q1 202512 holders, $986m42 holders, $98.4bn
Q2 202514 holders, $1.2bn43 holders, $93.2bn
Q3 202517 holders, $1.9bn39 holders, $86.7bn
Q4 202514 holders, $2.1bn41 holders, $123bn
Q1 202612 holders, $1.8bn39 holders, $106bn
Q2 20269 holders, $2.7bn44 holders, $132bn
MEDP

Medpace HLDGS Inc

Holders
18
Reported value
$1.3bn
Buyers
9
Sellers
9

Breadth 0 among 94 comparable managers.

Health care services and researchHealthcare: biopharma and medtech · L3VLUP
LLY

Eli Lilly & Co

Holders
43
Reported value
$110bn
Buyers
29
Sellers
17

Breadth +12 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2024

Among the 48 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only MEDP (5)

Baillie Gifford & Co, PDT Partners LLC, Point72 Asset Management LP, Renaissance Technologies LLC, Voloridge Investment Management LLC

Only LLY (30)

Acadian Asset Management LLC, AllianceBernstein LP, Artisan Partners LP, Balyasny Asset Management LLC, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Citadel Advisors LLC, Coatue Management LLC, Dodge & Cox, ExodusPoint Capital Management LP, Fidelity (FMR LLC), GAMCO Investors Inc, Hudson Bay Capital Management LP, Jane Street Group LLC, Janus Henderson Group Ltd, Marshall Wace LLP, MFS Investment Management, Millennium Management LLC, Moore Capital Management LP, Neuberger Berman Group LLC, Schonfeld Strategic Advisors LLC, Squarepoint Ops LLC, Susquehanna International Group LLP, T. Rowe Price Associates Inc, and 5 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →